OPKO Health Q1 Earnings Call Highlights Progress in ModeX Pipeline and Financials
OPKO Health reported Q1 2026 results, highlighting progress in its ModeX Therapeutics pipeline, including five clinical programs and a potential in-vivo CAR-T trial by late 2026. The company also noted financial improvements, including narrower losses and a Q2 revenue guidance of $127M–$132M. Additionally, OPKO is restructuring its diagnostics division and expects growth in 4Kscore volumes if Medicare coverage updates are favorable.
Tickers: $MRK
Topics: Clinical Trials Earnings Call Financial Performance Pipeline Development Strategic Restructuring